Oncology Deal Benchmarks
Licensing deals, acquisitions, and collaborations in solid tumors and hematologic malignancies. Benchmarks derived from 428 verified transactions.
428
Total Deals
$1.4B
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
97
license
95
acquisition
93
collaboration
64
option
75
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Dizal Pharmaceutical → AstraZeneca Zegfrovy | license | $600M | $1.5B | Jul 2026 |
Hansoh Pharmaceutical → GSK risvutatug rezetecan (ris-rez) / HS-20093 | license | $185M | $1.7B | Jul 2026 |
Antares → Novartis multi-target oncology discovery collaboration | collaboration | $105M | $1.9B | Jun 2026 |
Xencor → Genentech XmAb24306 | co development | $120M | — | Jun 2026 |
CytomX → Amgen Probody bispecific (EGFR) | co development | $40M | — | Jun 2026 |
Nuvalent, Inc. → GSK Nuvalent pipeline (targeted kinase inhibitors for NSCLC) | acquisition | $10.6B | $10.6B | Jun 2026 |
Orionis → Novartis molecular glue programs | collaboration | $40M | $1.4B | Jun 2026 |
Jiangsu Hengrui → Bristol Myers Squibb 13 early-stage oncology/hematology/immunology programs | collaboration | $600M | $15.2B | Jun 2026 |
Hengrui → Bristol Myers Squibb 13-program oncology/hematology/immunology collaboration | collaboration | $600M | $15.2B | Jun 2026 |
Nurix Therapeutics → Roche BTK degrader program | collaboration | $700M | $2.3B | Jun 2026 |
Benchmark Your Oncology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 428 verified oncology transactions.
Run Oncology Benchmark